Precigen to participate in a fireside chat hosted by cantor fitzgerald to discuss prgn-2012 adenoverse immunotherapy for the treatment of recurrent respiratory papillomatosis

Germantown, md. , march 12, 2024 /prnewswire/ -- precigen, inc. (nasdaq: pgen), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that cantor fitzgerald will be hosting a virtual fireside chat with precigen on monday, march 25, 2024 at 1:00 pm et to discuss the investigational prgn-2012 adenoverse ™  immunotherapy for the treatment of recurrent respiratory papillomatosis (rrp).
PGEN Ratings Summary
PGEN Quant Ranking